Tailin Biotech announced that the company held a board of directors and supervisors meeting on March 11, 2025 to review and approve the plan to repurchase the company's shares. The company plans to use its own funds and/or self-raised funds to repurchase some public shares through centralized bidding transactions for employee stock ownership plans. The repurchase price is not more than RMB 27.56 per share, and the total repurchase capital is not less than RMB 20 million and not more than RMB 40 million. The repurchase implementation period is 12 months from the date the board of directors reviews and approves the repurchase plan.

Zhitongcaijing · 03/11 11:17
Tailin Biotech announced that the company held a board of directors and supervisors meeting on March 11, 2025 to review and approve the plan to repurchase the company's shares. The company plans to use its own funds and/or self-raised funds to repurchase some public shares through centralized bidding transactions for employee stock ownership plans. The repurchase price is not more than RMB 27.56 per share, and the total repurchase capital is not less than RMB 20 million and not more than RMB 40 million. The repurchase implementation period is 12 months from the date the board of directors reviews and approves the repurchase plan.